Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
55 hedge funds and large institutions have $157M invested in Vincerx Pharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 10 closing their positions.
383% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 6
2% less funds holding
Funds holding: 56 → 55 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $249M → $157M (-$92.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.42M |
| 2 |
CC
Clearline Capital
New York
|
+$1.63M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$1.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.49M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$999K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$7.28M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.2M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.23M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.22M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.01M |
VINC Hedge Fund Activity: Q4 2021 in Review
55 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2021, worth a combined $157M — down 37% from $249M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of VINC and 9 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 29 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $3.42M. The largest seller was Boxer Capital, exiting entirely with an estimated $7.28M sold.
- 55 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2021, down from 56 in Q3 2021.
- Funds reported $157M of Vincerx Pharma, Inc. Common Stock stock for Q4 2021, down 37% quarter-over-quarter.
- 9 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2021 and 10 closed out, a net change of -1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2021 was Rubric Capital Management (New York), an estimated $3.42M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2021 was Boxer Capital, an estimated $7.28M sold.
Based on aggregated 13F filings for Q4 2021.